Alexion Announces Plans To Initiate Phase 3 Study Of Ultomiris In Hospitalized Patients With Severe…
Alexion Pharmaceuticals, Inc. announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are…
Read More...
Read More...
